Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992355 | 0.90 | MAPT (0.39) | GBA1MAPTGLSALDH1A1GUSB | |
| SCHEMBL16576128 | 0.84 | FNTA (0.36) | MAPTALDH1A1 | |
| SCHEMBL25884344 | 0.83 | NOTUM (0.49) | GBA1GLSGUSB | |
| SCHEMBL23696408 | 0.82 | ADRB2 (0.40) | GBA1MAPTGLS | |
| SCHEMBL25446872 | 0.81 | GLS (0.37) | GBA1GLSALDH1A1GUSB | |
| SCHEMBL25729664 | 0.80 | GLS (0.38) | GBA1MAPTGLS | |
| SCHEMBL22861720 | 0.79 | GBA1 (0.44) | GBA1 | |
| SCHEMBL9889152 | 0.79 | MAPT (0.39) | L3MBTL1MAPT | |
| SCHEMBL23635741 | 0.78 | HDAC1 (0.46) | — | |
| SCHEMBL16674334 | 0.78 | GLS (0.40) | GBA1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GBA1 3212/4885L3MBTL1 1394/4885MAPT 2459/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GBA1 3212/4885L3MBTL1 1394/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.